Items Tagged ‘T-Cell Non-Hodgkin’s Lymphoma’

August 16th, 2016

Opdivo® Highly Effective for Some Patients with Lymphomas

By

The immunotherapeutic agent, Opdivo® (nivolumab), appears to provide long-lasting anti-cancer activity among some patients who have received extensive prior therapy for both B- and T-cell lymphomas. These results were recently published in the Journal of Clinical Oncology. Lymphomas are a type of cancer that arise in immune cells. There are two main types of immune […]

View full entry

Tags: diffuse large B-cell lymphoma, Follicular Lymphoma, Lymphoma, News, nivolumab, Non-Hodgkin's Lymphoma, opdivo, peripheral T-cell lymphoma, T-Cell Non-Hodgkin's Lymphoma


June 20th, 2016

CAR Therapy Effective in Advanced Lymphoma

By

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types of lymphomas. This type of treatment is continuing to produce impressive results, and is demonstrating effectiveness in several different types […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, asco, CAR, CAR T, chimeric antigen receptor, Follicular Lymphoma, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Leukemia, Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma


January 19th, 2015

FDA Grants Fast Track Designation to SGX301 for First-Line Treatment of Cutaneous T-Cell Lymphoma

By

The U. S. Food and Drug Administration has granted Fast Track designation the synthetic hypericin (SGX301) development program for the first-line treatment of cutaneous T-cell lymphoma. Fast Track designation from the FDA is reserved for drugs that demonstrate the potential to address an unmet medical need for a serious or life-threatening condition. SGX301 previously received […]

View full entry

Tags: cutaneous lymphoma, hypericin, News, Non-Hodgkin's Lymphoma, photodynamic therapy, sgx301, T-Cell Non-Hodgkin's Lymphoma


December 17th, 2014

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment

By

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft function due to their need for HIV medications. Results from the clinical trial, presented at the American Society of Hematology […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Follicular Lymphoma, General HIV Related Cancers, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, hiv, hiv cancer, HIV Related Cancers, Indolent/Low Grade Non-Hodgkin's Lymphoma, Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, nhl


July 24th, 2014

FDA Approves Beleodaq for Peripheral T-cell Lymphoma

By

The FDA announces its approval of Beleodaq (belinostat), a histone deacetylase inhibitor for treating peripheral T-cell lymphoma (PTCL), based on the results of the BELIEF study that found an overall response rate of nearly 26% among treated patients. PTCL accounts for about~15% of all non-Hodgkin’s lymphoma (NHL) cases in North America each year.  Historically treatment […]

View full entry

Tags: beleodaq, belinostat, News, ptcl, T-Cell Non-Hodgkin's Lymphoma


September 4th, 2013

Celiac Disease Associated with Higher Risk of Lymphoma

By

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease is an autoimmune disorder of the small intestine characterized by intolerance to gluten, which is a […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Follicular Lymphoma, Health and Wellness, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma, Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma, Recurrent Non-Hodgkin's Lymphoma, Screening/Prevention Non-Hodgkin's Lymphoma, T-Cell Non-Hodgkin's Lymphoma


May 23rd, 2012

Targeted Agent Xalkori May Benefit Children with Anaplastic Lymphoma

By

The targeted agent Xalkori® (crizotinib) appears to drastically reduce the size of tumors in children with refractory anaplastic large cell lymphoma, according to the results of a phase I study that will be presented at the annual meeting of the American Society of Clinical Oncology in June. Xalkori is a targeted oral medication that blocks […]

View full entry

Tags: General Neuroblastoma, Neuroblastoma, News, Non-Hodgkin's Lymphoma, T-Cell Non-Hodgkin's Lymphoma


March 14th, 2012

Lymphoma During Pregnancy Can Have Good Outcomes

By

Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester of pregnancy, as well as women who deferred treatment until after delivery. These results were presented at the 2011 annual meeting […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Early Stage Hodgkin's Lymphoma, Follicular Lymphoma, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma, T-Cell Non-Hodgkin's Lymphoma


May 23rd, 2011

Many Patients with “Chemo Brain” Recover within Five Years

By

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist for more than five years after treatment. These findings were recently reported in the Journal of Clinical Oncology. Chemo brain refers […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Adult Acute Lymphoblastic Leukemia, Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Allogeneic Stem Cell Transplant, Childhood Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Early Stage Hodgkin's Lymphoma


April 19th, 2011

Additional Rare Cancer Cases Reported Among Users of TNF Blockers

By

The US Food and Drug Administration (FDA) has received additional reports of a rare type of cancer—hepatosplenic T-cell lymphoma—primarily among adolescents and young adults who are being treated for Crohn’s disease or ulcerative colitis with medications known as tumor necrosis factor (TNF) blockers as well as azathioprine and/or mercaptopurine. TNF blockers include Remicade® (infliximab), Enbrel® […]

View full entry

Tags: Health and Wellness, Non-Hodgkin's Lymphoma, T-Cell Non-Hodgkin's Lymphoma


February 3rd, 2011

Folotyn Benefits Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

By

In the Phase II PROPEL study, 29% of patients with relapsed or refractory peripheral T-cell lymphoma (a type of non-Hodgkin’s lymphoma) experienced a complete or partial disappearance of detectable cancer following treatment with Folotyn® (pralatrexate). These results—published in the Journal of Clinical Oncology—formed the basis for the approval of Folotyn for this disease. Peripheral T-cell […]

View full entry

Tags: News, Non-Hodgkin's Lymphoma, T-Cell Non-Hodgkin's Lymphoma


March 15th, 2010

Children and Teens Have Better NHL Survival than Young Adults

By

Even after accounting for stage at diagnosis and subtype of non-Hodgkin’s lymphoma (NHL), children and teens with NHL have better survival than young adults with NHL. These results were published in the Archives of Pediatrics and Adolescent Medicine. Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the cells of the lymph system. […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Indolent/Low Grade Non-Hodgkin's Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma, Recurrent Non-Hodgkin's Lymphoma, T-Cell Non-Hodgkin's Lymphoma


December 10th, 2008

Pralatrexate Shows Promise Against Peripheral T-cell Lymphoma

By

Pralatrexate Shows Promise Against Peripheral T-cell Lymphoma In a Phase II clinical trial, 27% of patients with relapsed or refractory peripheral T-cell lymphoma (a type of non-Hodgkin?s lymphoma) experienced a complete or partial disappearance of detectable cancer following treatment with the investigational drug pralatrexate. These results were presented at the 50th Annual Meeting of the […]

View full entry

Tags: T-Cell Non-Hodgkin's Lymphoma